Articles
Page 17 of 19
-
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P317
-
A cost-effectiveness analysis of Maraviroc in treatment-experienced HIV patients in Scotland
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P315 -
The use of enfuvirtide-based HAART regimens in HIV patients undergoing chemotherapy for lymphoma
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P291 -
Increased ribavirin dose in HIV/HCV co-infected patients leads to increased serum concentration of ribavirin
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P287 -
HCV genotypes distribution in the Nizhny Novgorod area HIV-positive population
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P285 -
Treatment outcome of chronic hepatitis C in HIV-infected patients at the Institute of Tropical Medicine, Antwerp, Belgium, from 2000 to 2008
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P283 -
Hepatitis B virus (HBV) genotype distribution and lamivudine-resistant mutations in HIV/HBV co-infected patients attending a Parisian hospital
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P279 -
Clinical and immuno-virologic outcome in a cohort of immigrant and native subjects with HIV infection in south-eastern Spain during the period 1998–2007
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P254 -
Peripheral blood CD4+ T-lymphocyte count influences cerebrospinal fluid cellular response in patients with HIV-related cryptococcal meningitis
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P252 -
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P248 -
Therapeutic drug monitoring of atazanavir in pregnancy
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P246 -
Impact on bone mineral density of tenofovir-containing HAART in HIV-1 infected children and adolescents: a report from 5 years of clinical experience
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P215 -
Analysis of HIV variants in blood and semen in serodiscordants by heteroduplex mobility assay
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P211 -
Analysis of viral load, CD4+ and CD8+ T-cell from HIV-1 infected patients enrolled in the AIDS programs from the city of Santos, Brazil
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P209 -
Raltegravir clinical efficacy against B subtype and non-B subtype HIV-1 is similar
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P207 -
Are non-B subtypes less susceptible to antiretroviral drugs? A bioinformatical approach to prediction of non-B subtype susceptibility
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P183 -
Etravirine protects the activity of darunavir in the DUET trials
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P181 -
Using the latest resistance score to predict etravirine (ETV) resistance in naïve and NNRTI-failing patients
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P179 -
Adherence to antiretroviral therapies in people with HIV infection: a qualitative approach from a narrative-based medicine study
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P177 -
Adherence to antiretroviral therapy among children receiving therapy in a resource-poor setting
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P175 -
Incidence of infections in treatment-experienced (TE) patients in the MOTIVATE studies of maraviroc (MVC) plus optimized background therapy (OBT)
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P154 -
Mitochondrial impairment in HIV-infected children
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P144 -
Mitochondrial effects of 3 years of CD4-guided HIV treatment interruption
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P142 -
Unexplained severe portal hypertension in HIV-infected patients: a new clinical entity?
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P138 -
Virologic failure and metabolic syndrome in patients with HIV infection
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P115 -
Metabolic syndrome among patients initiating HAART and outcome in Southern India
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P111 -
An audit of cardiovascular disease risk management in HIV-infected patients attending a northern English hospital
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P107 -
Effects of highly active antiretroviral therapy (HAART) on platelet activating factor (PAF) metabolism in HIV-infected patients: in vivo results
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P105 -
Experience of myocardial infarction in a Glasgow HIV cohort
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P103 -
Cardiovascular risk estimation in Spanish HIV-infected patients: a multicenter cohort study
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P92 -
Anti-inflammatory effect of Omacor during combination antiretroviral therapy: a 12-weeks randomised, double-blind, placebo-controlled trial
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P90 -
Abacavir and cardiovascular risk in HIV-infected patients: does T-lymphocyte hyperactivation exert a pathogenic role?
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P88 -
Efficacy and safety of ritonavir-boosted fosamprenavir (FPV/r) in HIV-infected patients: 48-week results from an observational study
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P86 -
Effect of age on response to and tolerability of highly active antiretroviral therapy: a case-control study
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P84 -
Good experience of enfurvitide in severely ill patients
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P82 -
Effectiveness and safety of HAART regimens containing tenofovir DF + saquinavir or fosamprenavir in HIV patients: sub-analysis from PROTECTION study
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P78 -
FREE trial: induction therapy with ART (abacavir/lamivudine/lopinavir/r) followed by maintenance regimen with triple NRTI, compared to continued ART
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P55 -
Efficacy and safety of switching from lopinavir/r to atazanavir/r in suppressed patients receiving a LPV/r-containing HAART: ATAZIP 96-week results
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P53 -
Etravirine use in clinical practice: 48-week data from a single centre cohort
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P49 -
Therapeutic options in heavily pretreated HIV-1 patients based on the genotypic resistance patterns
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P47 -
O423 Risk of new AIDS-defining events in patients with advanced immunodeficiency during suppressive HAART: results from the German ClinSurv cohort
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O45 -
Excellent short-term CD4 recovery with a PI- and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P45 -
O421 When to start therapy? The patient's viewpoint
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O43 -
O333 Treatment discontinuation and virological failure amongst HIV-positive individuals starting second-line combination antiretroviral therapy (cART)
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O37 -
O223 Antiretroviral Pregnancy Registry (APR) at 10,000 prospective reports
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O22 -
Raltegravir: a potent and safe integrase inhibitor with a favourable impact on cardiovascular and liver profile
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P20 -
Comparing the efficacy of Truvada® and Kivexa® combination therapy in HAART-naive individuals with different viral loads
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P14 -
Efficacy and safety of TDF/FTC-containing first-line HAART in clinical practice – 2-year data from the German Outpatient Cohort
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P12 -
O125 Impact of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as tablets and capsules in African patients
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O10 -
Immune restoration during HAART: 8-year follow-up in HIV-positive patients with sustained virological suppression
Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P10